DSS Converts $12M Loan to Equity Stake in Impact Biomedical
The deal eliminates Impact’s debt obligations while giving DSS a major position in common shares.
July 31, 2025
DSS Converts Impact Biomedical Debt to Equity in Strategic Shift
On July 21, DSS turned a $12 million loan into equity—swapping debt for 31.9 million shares of Impact Biomedical’s common stock. That move cleared the loan from Impact’s books and gave DSS a substantial ownership stake in return.
The loan itself dates back to March 2023, when DSS issued a revolving promissory note to Impact Biomedical. The terms were later adjusted in January 2024. Maturity was extended. The revolving feature was removed. Repayment terms were locked in. The interest rate was updated to reflect market conditions. By mid-2025, however, DSS opted for a new path forward.
That path took shape as a debt conversion agreement. DSS settled not only the outstanding principal and interest on the original loan, but also any credit or services it had provided since June 21. In exchange, it received freely tradable shares in Impact Biomedical, closing out the debt entirely.
With the agreement now complete, both sides come away with something tangible. DSS gains a direct equity position. Impact clears its largest financing obligation and reclaims flexibility.
The result: a restructured relationship. Not lender and borrower—but shareholders and partners.
Share
Read More Articles
